Theralase Techs Inc (TLTFF)

Last Price0.2115

Change+0.0090 (4.44%)

OP · Last Trade: Apr 3rd, 4:15 PM EDT

Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus

Toronto, Ontario--(Newsfile Corp. - March 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile · March 17, 2026

Theralase(R) Closes $1.1 M Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...

Via Newsfile · March 10, 2026

Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer

Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical...

Via Newsfile · March 9, 2026

Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress

This Press Release identifies that Dr. Kulkarni has participated in a medical advisory position for Theralase(R) in the past.Toronto, Ontario--(Newsfile...

Via Newsfile · February 20, 2026

Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congressnewsfilecorp.com

Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile · February 17, 2026

Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile · February 10, 2026

Theralase(R) Provides Update on Bladder Cancer Clinical Study

Toronto, Ontario--(Newsfile Corp. - February 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...

Via Newsfile · February 4, 2026

Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study

Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile · February 2, 2026

Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer

The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with...

Via Newsfile · January 12, 2026

Theralase(R) Closes $1.3 M Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile · December 23, 2025

Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing

Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile · December 12, 2025

Theralase(R) Investor Conference Call Reminder

Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile · November 17, 2025

Theralase(R) Releases 3Q2025 Financial Statements

Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering...

Via Newsfile · November 10, 2025

Theralase(R) Demonstrates Effectiveness of X-Ray-Activated Drug

Toronto, Ontario--(Newsfile Corp. - November 3, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile · November 3, 2025

Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus

Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...

Via Newsfile · September 24, 2025

Theralase(R) Extends Warrants

Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile · August 29, 2025

Theralase(R) Releases 2Q2025 Financial Statements

Toronto, Ontario--(Newsfile Corp. - August 26, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile · August 26, 2025

Theralase(R) Closes Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - July 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile · July 28, 2025

Theralase(R) Extends Warrants

Toronto, Ontario--(Newsfile Corp. - June 27, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...

Via Newsfile · June 27, 2025

Theralase(R) Closes Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - June 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile · June 17, 2025

Theralase Completes Annual General and Special Meeting

Toronto, Ontario--(Newsfile Corp. - June 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...

Via Newsfile · June 12, 2025

Theralase Annual General Meeting

Toronto, Ontario--(Newsfile Corp. - June 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile · June 5, 2025

Theralase(R) 1Q2025 Financial Statements

Toronto, Ontario--(Newsfile Corp. - May 30, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile · May 30, 2025

CORRECTION FROM SOURCE: Theralase to Present Groundbreaking Research at ASTRO 2025

This Press Release removes references to preclinical data that has not yet been presented.Toronto, Ontario--(Newsfile Corp. - May 29, 2025)...

Via Newsfile · May 29, 2025

Theralase to Present Groundbreaking Research at ASTRO 2025

Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile · May 28, 2025